亿腾嘉和(06998)发布年度业绩，归母利润3.99亿元同比增加2.93%

智通财经

Mar 27

智通财经APP讯，亿腾嘉和(06998)发布截至2025年12月31日止年度业绩，该集团取得收入人民币24.87亿元(单位下同)，同比减少2.3%;母公司拥有人应占利润3.99亿元，同比增加2.93%;每股基本盈利23.8分。

公告称，于2025年，创新药唯思沛^®的销售总收入为1.89亿元，较2024年增加1.12亿元，增幅为144.0%。公司加大了唯思沛^®的销售推广力度，带动其销售实现良好增长。另一方面，于2025年，稳可达^®的销售总收入较上年减少1.1亿元，降幅为46.1%。主要原因为于2025年，泊帕类产品均处于市场调整阶段，终端市场整体需求下降。希刻劳^®于上半年的收入为2.64亿元，而于下半年则为5.43亿元。与2025年上半年相比，希刻劳^®于下半年的收入大幅增加，而全年收入与去年基本持平，略有下降。2025年上半年希刻劳^®销量下滑，主要由于希刻劳^®零售市场受到2025年上半年中国抗菌药物市场放缓影响，以及集团调整了零售销售策略，优先于全国及区域连锁药房合作，减少与小型批发商的业务往来。然而，随着创新性抗菌药物逐步增加及相关适应症患者患病率缓慢上升，集团零售业务于下半年恢复增长，与集团战略计划一致。报告期内，希刻劳^®的平均售价维持稳定。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2622873206"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2622873206\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2622873206?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-27 23:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622873206","market":"fut","top_or_hot":-1,"title":"亿腾嘉和(06998)发布年度业绩，归母利润3.99亿元 同比增加2.93%","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/06998\">亿腾嘉和</a>(06998)发布截至2025年12月31日止年度业绩，该集团取得收入人民币24.87亿元(单位下同)，同比减少2.3%;母公司拥有人应占利润3.99亿元，同比增加2.93%;每股基本盈利23.8分。</p><p>公告称，于2025年，创新药唯思沛<sup>®</sup>的销售总收入为1.89亿元，较2024年增加1.12亿元，增幅为144.0%。公司加大了唯思沛<sup>®</sup>的销售推广力度，带动其销售实现良好增长。另一方面，于2025年，稳可达<sup>®</sup>的销售总收入较上年减少1.1亿元，降幅为46.1%。主要原因为于2025年，泊帕类产品均处于市场调整阶段，终端市场整体需求下降。希刻劳<sup>®</sup>于上半年的收入为2.64亿元，而于下半年则为5.43亿元。与2025年上半年相比，希刻劳<sup>®</sup>于下半年的收入大幅增加，而全年收入与去年基本持平，略有下降。2025年上半年希刻劳<sup>®</sup>销量下滑，主要由于希刻劳<sup>®</sup>零售市场受到2025年上半年中国抗菌药物市场放缓影响，以及集团调整了零售销售策略，优先于全国及区域连锁药房合作，减少与小型批发商的业务往来。然而，随着创新性抗菌药物逐步增加及相关适应症患者患病率缓慢上升，集团零售业务于下半年恢复增长，与集团战略计划一致。报告期内，希刻劳<sup>®</sup>的平均售价维持稳定。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>亿腾嘉和(06998)发布年度业绩，归母利润3.99亿元 同比增加2.93%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n亿腾嘉和(06998)发布年度业绩，归母利润3.99亿元 同比增加2.93%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-27 23:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1421049.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，亿腾嘉和(06998)发布截至2025年12月31日止年度业绩，该集团取得收入人民币24.87亿元(单位下同)，同比减少2.3%;母公司拥有人应占利润3.99亿元，同比增加2.93%;每股基本盈利23.8分。公告称，于2025年，创新药唯思沛®的销售总收入为1.89亿元，较2024年增加1.12亿元，增幅为144.0%。公司加大了唯思沛®的销售推广力度，带动其销售实现良好增长。...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1421049.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1421049.html","article_id":"2622873206","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622873206","pubTimestamp":1774623855,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，亿腾嘉和 发布截至2025年12月31日止年度业绩，该集团取得收入人民币24.87亿元，同比减少2.3%;母公司拥有人应占利润3.99亿元，同比增加2.93%;每股基本盈利23.8分。公告称，于2025年，创新药唯思沛的销售总收入为1.89亿元，较2024年增加1.12亿元，增幅为144.0%。希刻劳于上半年的收入为2.64亿元，而于下半年则为5.43亿元。与2025年上半年相比，希刻劳于下半年的收入大幅增加，而全年收入与去年基本持平，略有下降。报告期内，希刻劳的平均售价维持稳定。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1583":"高瓴概念","BK1161":"生物科技","BK1574":"生物医药B类股","06998":"亿腾嘉和"},"translate_title":"Yiteng Jiahe (06998) released its annual results, with profit attributable to the parent of 399 million yuan, a year-on-year increase of 2.93%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06998":1.5},"content_text":"智通财经APP讯，亿腾嘉和(06998)发布截至2025年12月31日止年度业绩，该集团取得收入人民币24.87亿元(单位下同)，同比减少2.3%;母公司拥有人应占利润3.99亿元，同比增加2.93%;每股基本盈利23.8分。公告称，于2025年，创新药唯思沛®的销售总收入为1.89亿元，较2024年增加1.12亿元，增幅为144.0%。公司加大了唯思沛®的销售推广力度，带动其销售实现良好增长。另一方面，于2025年，稳可达®的销售总收入较上年减少1.1亿元，降幅为46.1%。主要原因为于2025年，泊帕类产品均处于市场调整阶段，终端市场整体需求下降。希刻劳®于上半年的收入为2.64亿元，而于下半年则为5.43亿元。与2025年上半年相比，希刻劳®于下半年的收入大幅增加，而全年收入与去年基本持平，略有下降。2025年上半年希刻劳®销量下滑，主要由于希刻劳®零售市场受到2025年上半年中国抗菌药物市场放缓影响，以及集团调整了零售销售策略，优先于全国及区域连锁药房合作，减少与小型批发商的业务往来。然而，随着创新性抗菌药物逐步增加及相关适应症患者患病率缓慢上升，集团零售业务于下半年恢复增长，与集团战略计划一致。报告期内，希刻劳®的平均售价维持稳定。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}